DSFIR Stock Overview
Provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
DSM-Firmenich AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €89.50 |
| 52 Week High | €124.85 |
| 52 Week Low | €82.56 |
| Beta | 0 |
| 1 Month Change | -7.62% |
| 3 Month Change | -7.90% |
| 1 Year Change | -12.81% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -24.00% |
Recent News & Updates
Is There An Opportunity With DSM-Firmenich AG's (AMS:DSFIR) 26% Undervaluation?
Apr 04
Investors Shouldn't Be Too Comfortable With DSM-Firmenich's (AMS:DSFIR) Earnings
Mar 08
Focusing On Taste, Texture, And Health Will Strengthen Future Prospects
Feb 23 The merger of DSM and Firmenich focuses on high-growth segments, enhancing revenue through synergies and achieving significant earnings improvements.Recent updates
Is There An Opportunity With DSM-Firmenich AG's (AMS:DSFIR) 26% Undervaluation?
Apr 04Investors Shouldn't Be Too Comfortable With DSM-Firmenich's (AMS:DSFIR) Earnings
Mar 08Focusing On Taste, Texture, And Health Will Strengthen Future Prospects
Feb 23 The merger of DSM and Firmenich focuses on high-growth segments, enhancing revenue through synergies and achieving significant earnings improvements.DSM-Firmenich AG's (AMS:DSFIR) Business Is Yet to Catch Up With Its Share Price
Jan 17Estimating The Fair Value Of DSM-Firmenich AG (AMS:DSFIR)
Dec 13We Think DSM-Firmenich (AMS:DSFIR) Has A Fair Chunk Of Debt
Oct 20DSM-Firmenich AG's (AMS:DSFIR) Popularity With Investors Is Under Threat From Overpricing
Sep 23A Look At The Intrinsic Value Of DSM-Firmenich AG (AMS:DSFIR)
Aug 28DSM-Firmenich AG's (AMS:DSFIR) Shareholders Might Be Looking For Exit
Jun 20Calculating The Intrinsic Value Of DSM-Firmenich AG (AMS:DSFIR)
May 24Here's Why DSM-Firmenich (AMS:DSFIR) Can Afford Some Debt
Apr 27Shareholder Returns
| DSFIR | NL Chemicals | NL Market | |
|---|---|---|---|
| 7D | 2.8% | 3.8% | 5.4% |
| 1Y | -12.8% | -20.1% | -13.9% |
Return vs Industry: DSFIR exceeded the Dutch Chemicals industry which returned -20.1% over the past year.
Return vs Market: DSFIR exceeded the Dutch Market which returned -13.9% over the past year.
Price Volatility
| DSFIR volatility | |
|---|---|
| DSFIR Average Weekly Movement | 4.1% |
| Chemicals Industry Average Movement | 3.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NL Market | 8.7% |
| 10% least volatile stocks in NL Market | 3.3% |
Stable Share Price: DSFIR has not had significant price volatility in the past 3 months compared to the Dutch market.
Volatility Over Time: DSFIR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1902 | 26,301 | Dimitri de Vreeze | www.dsm-firmenich.com |
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients.
DSM-Firmenich AG Fundamentals Summary
| DSFIR fundamental statistics | |
|---|---|
| Market cap | €23.18b |
| Earnings (TTM) | €250.00m |
| Revenue (TTM) | €12.80b |
94.6x
P/E Ratio1.8x
P/S RatioIs DSFIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DSFIR income statement (TTM) | |
|---|---|
| Revenue | €12.80b |
| Cost of Revenue | €8.55b |
| Gross Profit | €4.25b |
| Other Expenses | €4.00b |
| Earnings | €250.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jul 31, 2025
| Earnings per share (EPS) | 0.95 |
| Gross Margin | 33.17% |
| Net Profit Margin | 1.95% |
| Debt/Equity Ratio | 21.0% |
How did DSFIR perform over the long term?
See historical performance and comparisonDividends
2.8%
Current Dividend Yield265%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/15 18:35 |
| End of Day Share Price | 2025/04/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DSM-Firmenich AG is covered by 57 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mutlu Gundogan | ABN AMRO Bank N.V. |
| Martin Schnee | AlphaValue |
| Alexander Sloane | Barclays |